110 related articles for article (PubMed ID: 2560213)
1. Opiate control of spontaneous locomotor activity in a urodele amphibian.
Deviche P; Lowry CA; Moore FL
Pharmacol Biochem Behav; 1989 Dec; 34(4):753-7. PubMed ID: 2560213
[TBL] [Abstract][Full Text] [Related]
2. Effects of corticotropin-releasing factor (CRF) and opiates on amphibian locomotion.
Lowry CA; Deviche P; Moore FL
Brain Res; 1990 Apr; 513(1):94-100. PubMed ID: 2161698
[TBL] [Abstract][Full Text] [Related]
3. Opioid kappa-receptor agonists suppress sexual behaviors in male rough-skinned newts (Taricha granulosa).
Deviche P; Moore FL
Horm Behav; 1987 Sep; 21(3):371-83. PubMed ID: 2822565
[TBL] [Abstract][Full Text] [Related]
4. Elevation of serum corticosterone in rats by bremazocine, a kappa-opioid agonist.
Fuller RW; Leander JD
J Pharm Pharmacol; 1984 May; 36(5):345-6. PubMed ID: 6145778
[TBL] [Abstract][Full Text] [Related]
5. Bremazocine-induced backwards walking behavior in rats is mediated via opioid kappa receptors.
Shearman GT; Stenfors C
Pharmacol Biochem Behav; 1986 Apr; 24(4):861-3. PubMed ID: 3012599
[TBL] [Abstract][Full Text] [Related]
6. Kappa-opiates and urination: pharmacological evidence for an endogenous role of the kappa-opiate receptor in fluid and electrolyte balance.
Huidobro-Toro JP; Parada S
Eur J Pharmacol; 1984 Dec; 107(1):1-10. PubMed ID: 6098480
[TBL] [Abstract][Full Text] [Related]
7. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.
Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
Neuroendocrinology; 1986; 42(1):75-81. PubMed ID: 3001565
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the respiratory depressant and analgesic effects of bremazocine, a kappa-agonist.
Pazos A; Tristán C; Flórez J
Life Sci; 1983; 33 Suppl 1():579-81. PubMed ID: 6319913
[TBL] [Abstract][Full Text] [Related]
9. Diuretic effect of bremazocine, a kappa-opioid with central and peripheral sites of action.
Salas SP; Roblero J; Ureta H; Huidobro-Toro JP
J Pharmacol Exp Ther; 1989 Sep; 250(3):992-9. PubMed ID: 2550625
[TBL] [Abstract][Full Text] [Related]
10. Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice.
Kuzmin A; Sandin J; Terenius L; Ogren SO
J Pharmacol Exp Ther; 2000 Dec; 295(3):1031-42. PubMed ID: 11082438
[TBL] [Abstract][Full Text] [Related]
11. Psychotomimesis mediated by kappa opiate receptors.
Pfeiffer A; Brantl V; Herz A; Emrich HM
Science; 1986 Aug; 233(4765):774-6. PubMed ID: 3016896
[TBL] [Abstract][Full Text] [Related]
12. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488.
Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
Neuroendocrinology; 1986; 42(1):82-7. PubMed ID: 3001566
[TBL] [Abstract][Full Text] [Related]
13. Bremazocine: a potent, long-acting opiate kappa-agonist.
Römer D; Büscher H; Hill RC; Maurer R; Petcher TJ; Welle HB; Bakel HC; Akkerman AM
Life Sci; 1980 Sep; 27(11):971-8. PubMed ID: 6253759
[No Abstract] [Full Text] [Related]
14. Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man.
Pfeiffer A; Knepel W; Braun S; Meyer HD; Lohmann H; Brantl V
Horm Metab Res; 1986 Dec; 18(12):842-8. PubMed ID: 3028922
[TBL] [Abstract][Full Text] [Related]
15. Kappa-receptor antagonist reverse 'non-opioid' stress-induced analgesia.
Panerai AE; Martini A; Sacerdote P; Mantegazza P
Brain Res; 1984 Jun; 304(1):153-6. PubMed ID: 6331578
[TBL] [Abstract][Full Text] [Related]
16. Effects of bremazocine on locomotor activity in DBA/2 and C57BL/6 mice.
Castellano C; Pavone F
Arch Int Pharmacodyn Ther; 1985 Nov; 278(1):45-52. PubMed ID: 4096608
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of nociceptive flexion reflex discharge by the kappa agonist bremazocine.
Banna NR; Al-Amin HA; Jabbur SJ
Neuropharmacology; 1987; 26(2-3):271-4. PubMed ID: 3035416
[TBL] [Abstract][Full Text] [Related]
18. Modulation of appetitively and aversively motivated behavior by the kappa opioid antagonist MR2266.
Fanselow MS; Calcagnetti DJ; Helmstetter FJ
Behav Neurosci; 1989 Jun; 103(3):663-72. PubMed ID: 2544207
[TBL] [Abstract][Full Text] [Related]
19. Bremazocine causes sympatho-inhibition and hypotension in rabbits by activating peripheral kappa-receptors.
Ensinger H; Hedler L; Szabo B; Starke K
J Cardiovasc Pharmacol; 1986; 8(3):470-5. PubMed ID: 2425160
[TBL] [Abstract][Full Text] [Related]
20. The role of CRF in the release of ACTH by opiate agonists and antagonists in rats.
Nikolarakis K; Pfeiffer A; Stalla GK; Herz A
Brain Res; 1987 Sep; 421(1-2):373-6. PubMed ID: 2825911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
